Co-diagnostics (CODX) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$721,386.00

Revenue (quarter)

$166,131.00

Revenue growth (year over year)

+1.98%

Gross profit (trailing twelve months)

$313,634.00

Gross margin

43.48%

Net income (trailing twelve months)

−$47.1M

Net income (quarter)

−$6.3M

Net income growth (year over year)

+18.71%

Net margin

−6523.05%

Return on equity

−174.77%

EPS (trailing twelve months)

−$25.89

Book value per share

$2.61

P/E (trailing twelve months)

—

Price to book

0.58

Debt to assets

23.38%

Payout ratio

—

Dividend yield

—

Company profile

Co-Diagnostics Inc is a molecular diagnostics company. The company develops, manufactures, licenses, and commercializes reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules (DNA or RNA), including molecular tools for detection of infectious diseases. CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and others. The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious diseases.

• Is Co-diagnostics (CODX) profitable?

  No. Co-diagnostics reported a net loss of $47.1M over the trailing twelve months.

• How much revenue does Co-diagnostics (CODX) make?

  Co-diagnostics generated $721,386.00 in revenue over the trailing twelve months, up 1.98% year over year.

• How do I buy stock in Co-diagnostics (CODX)?

  CODX trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.